It seems that the oral treatment of PPAR syntetic ligand decreases inflammatory cytokines and suppresses angiogenesis, and PPAR syntetic ligand has been used in the treatment of metabolic syndrome, diabetes and dyslipidemia. Here, PPARA is linked to metabolic syndrome.